Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across
Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in
First patient dosed in global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC
On track for multiple clinical data readouts in 2027 and more than 2,000 patients dosed across the portfolio by mid-year
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027. We plan to aggressively pursue additional combination opportunities that can further our efforts to develop CR-001 as a best-in-class IO backbone therapy. Building on the pipeline progress we outlined last month, we are pleased to have now commenced patient dosing in the global APOLLO trial of CR-002, our PD-L1-targeted ADC,” said
Recent Business Highlights & Anticipated Milestones
CR-001, PD-1 x VEGF Bispecific Antibody
Clinical Execution Progress in ASCEND, a Global Phase 1/2 Trial of CR-001
- In
October 2026 , Crescent announced completion of dose escalation in ASCEND, a global Phase 1/2 trial of CR-001, its investigational PD-1 x VEGF bispecific, with patients enrolled across several tumor types at clinical sites inthe United States ,Europe andSouth Korea . - Crescent is on track to report initial monotherapy data from ASCEND in the first quarter of 2027, including:
- Preliminary antitumor response as measured by overall response rate (ORR) from a first-line NSCLC cohort of up to 12 patients.
- Safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 treatment-naïve and previously treated patients across multiple solid tumor types.
- Patient dosing has commenced in ASCEND expansion cohorts which are evaluating CR-001 with various standard of care chemotherapy combinations across several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers. Crescent is on track to report initial data from hundreds of patients in mid-2027 (Q2/Q3).
- Data from the expansion cohorts, along with monotherapy data from ASCEND, will inform future clinical development for CR-001. Pending results and further interactions with regulators, Crescent plans to initiate the first of multiple Phase 3 trials of CR-001 in early 2028.
- Trial in progress posters of the ASCEND study design were featured during the
European Society for Medical Oncology (ESMO) 2026Congress heldOctober 23-27, 2026 inMadrid, Spain and at theSociety for Immunotherapy of Cancer (SITC) 2026 Annual Meeting heldNovember 4-8, 2026 inPhoenix, Arizona .
Multiple Studies Evaluating CR-001 in Combination with Novel ADCs
- Under a collaboration agreement, Crescent granted Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., (“Kelun-Biotech”) exclusive rights to research, develop, and commercialize CR-001 (also known as SKB118) in
Greater China . Both Kelun-Biotech and Crescent have rights to independently develop CR-001 in combinations, including with their respective antibody-drug conjugate (ADC) pipelines. - Kelun-Biotech is conducting multiple Phase 2 trials in
China evaluating CR-001 (SKB118) in combination with sacituzumab tirumotecan (sac-TMT), its TROP2-directed ADC. Initial data from a study in patients with locally advanced or metastatic NSCLC are expected in mid-2027 (Q2/Q3). Additional studies are underway in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-squamous NSCLC who have failed EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, as well as in patients with advanced solid tumors. - A Phase 1/2 trial of CR-001 (SKB118) in combination with CR-003 (also known as SKB105), an integrin-beta 6 (ITGB6)-directed ADC, is expected to commence in the first half of 2027.
CR-002, Topoisomerase Inhibitor ADC Targeting PD-L1
- Earlier this month, the first patient was dosed in the global Phase 1/2 APOLLO trial of CR-002, a topoisomerase inhibitor ADC targeting programmed cell death ligand 1 (PD-L1). APOLLO is designed to enroll patients in
the United States ,Europe andAsia Pacific with advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. The study’s dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants with the opportunity for additional participants in expansion cohorts. - Crescent anticipates reporting initial data from APOLLO in the second half of 2027, including safety, tolerability, pharmacokinetics and preliminary antitumor activity.
- Preclinical data for CR-002 will be featured in a poster presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and
Cancer Therapeutics being heldNovember 18-20, 2026 inBarcelona, Spain .
CR-003, Topoisomerase Inhibitor ADC Targeting ITGB6
- Kelun-Biotech granted Crescent exclusive rights to research, develop, and commercialize CR-003 (SKB105), an ITGB6-targeted ADC, in
the United States ,Europe and all markets outside ofGreater China . - A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in
China is ongoing and proof-of-concept data are expected in the first quarter of 2027. Crescent plans to leverage data generated inChina to support the global clinical development of CR-003 (SKB105).
Third Quarter 2026 Financial Results
Cash position: Cash and cash equivalents were
Research and development (R&D) expenses: R&D expenses were
General and administrative (G&A) expenses: G&A expenses were
Net loss: Net loss was
Shares outstanding: As of
About
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, beliefs, or strategies regarding the future of its pipeline and business including, without limitation: the timing and success of clinical data from the ASCEND monotherapy and combination trials of CR-001; the potential initiation and success of Phase 3 studies of CR-001; the timing and success of the Phase 2 combination trials for CR-001 and sac-TMT, including the potential initiation of additional ADC combination studies by Kelun-Biotech; the trial design, indication selection, and timing and success of clinical data for the global Phase 1/2 APOLLO trial of CR-002; the timing and success of clinical data from the Phase 1/2 trial of CR-003 as generated by Kelun-Biotech in China; the expected benefits or opportunities with respect to CR-001, CR-002, and CR-003, including each product’s potential to act as a single agent or combination agent; the anticipated number of patients dosed across the portfolio; and Crescent’s anticipated cash runway. Forward-looking statements generally relate to future events or future financial or operating performance. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects and involve a number of risks, uncertainties or other assumptions that may cause actual performance to be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties include, but are not limited to: the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized or may take longer to realize than anticipated; Crescent’s limited operating history, including with respect to clinical trials; Crescent’s historical losses and any future ability to generate revenue; Crescent’s ability to raise capital to support its business plans; risks associated with clinical development and regulatory approval; risks related to Crescent’s intellectual property; Crescent’s reliance on third parties, including to help develop its product candidates, run its clinical trials, and manufacture its product candidates; significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks; risks related to the current macroeconomic environment, including fluctuating interest rates, barriers to trade, changes to fiscal and monetary policy or government budget dynamics, geopolitical factors, including the ongoing conflicts in Iran and between Russia and Ukraine and the responses thereto, and supply chain disruptions, as well as those factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent’s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements.
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited) | |||||||||||||||
| Three Months Ended | Nine Months Ended | Three Months Ended | Nine Months Ended | ||||||||||||
| License agreement revenue | $ | 3,117 | $ | 4,156 | $ | — | $ | — | |||||||
| Operating expenses | |||||||||||||||
| Research and development | 34,305 | 71,598 | 20,347 | 43,059 | |||||||||||
| General and administrative | 8,719 | 25,328 | 5,538 | 18,081 | |||||||||||
| Total operating expenses | 43,024 | 96,926 | 25,885 | 61,140 | |||||||||||
| Other income | — | 1,770 | — | — | |||||||||||
| Loss from operations | (39,907 | ) | (91,000 | ) | (25,885 | ) | (61,140 | ) | |||||||
| Other income (expense) | 2,181 | 5,154 | 1,278 | (405 | ) | ||||||||||
| Net loss and comprehensive loss | $ | (37,726 | ) | $ | (85,846 | ) | $ | (24,607 | ) | $ | (61,545 | ) | |||
| Net loss per share attributable to ordinary shareholders, basic and diluted | $ | (0.90 | ) | $ | (2.37 | ) | $ | (1.27 | ) | $ | (7.89 | ) | |||
| Net loss per share attributable to Series A non-voting convertible preferred shareholders, basic and diluted | $ | (899.31 | ) | $ | (2,368.17 | ) | $ | (1,266.44 | ) | $ | (7,891.38 | ) | |||
| Weighted-average ordinary shares outstanding used in computing net loss per share to ordinary shareholders, basic and diluted | 39,056,224 | 33,360,473 | 16,540,771 | 6,640,402 | |||||||||||
| Weighted-average Series A non-voting convertible preferred shares outstanding used in computing net loss per share to Series A non-voting convertible preferred shareholders, basic and diluted | 2,890 | 2,890 | 2,890 | 1,160 | |||||||||||
| Summary Balance Sheet Data (in thousands) (Unaudited) | |||||||
| Assets | |||||||
| Cash | $ | 289,357 | $ | 213,192 | |||
| Other assets | 10,146 | 27,101 | |||||
| Total Assets | $ | 299,503 | $ | 240,293 | |||
| Liabilities and Shareholders' Equity | |||||||
| Liabilities | $ | 25,224 | $ | 37,281 | |||
| Shareholders' equity | 274,279 | 203,012 | |||||
| Total liabilities and shareholders' equity | $ | 299,503 | $ | 240,293 | |||
Contacts
Investors
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
Source: 